As eIF4A1 has been identified as a potential prognostic marker in various cancers [38, 40, 41], these antibodies could be employed in immunohistochemical analyses of patient tissues to assess eIF4A1 expression patterns in tumor progression and treatment response. Here, EIF4A1 is linked to neoplasm.